Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital:: an 8-year-experience:: 1995-2002

被引:24
作者
Mohr, JF
Jones, A
Ostrosky-Zeichner, L
Wanger, A
Tillotson, G
机构
[1] Univ Texas, Hlth Sci Ctr, Div Infect Dis, Houston, TX 77225 USA
[2] Univ Texas, Hlth Sci Ctr, Ctr Study Emerging & Reemerging Pathogens, Houston, TX USA
[3] Univ York, York YO10 5DD, N Yorkshire, England
[4] Univ Texas, Hlth Sci Ctr, Dept Pathol, Div Microbiol, Houston, TX USA
[5] Publ Hlth Res Inst, Newark, NJ 07730 USA
关键词
Pseudomonas aeruginosa; fluoroquinolones; resistance;
D O I
10.1016/j.ijantimicag.2004.06.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Increasing resistance in Pseudomonas aeruginosa to multiple antibiotics has been observed and is posing therapeutic dilemmas. Antibiotic utilization is one factor that has been associated with the emergence of antimicrobial resistance. We examined the overall and specific antimicrobial use in relation to changes in susceptibility patterns in P. aeruginosa. Regression analysis was performed to explore the relationships between annual antibiotic use and the incidence of resistant P. aeruginosa. There were statistically significant relationships between increasing anti-pseudomonal cephalosporin and levofloxacin use and the increasing incidence of ciprofloxacin resistant P aeruginosa. However, there was not an association between other fluoroquinolone or overall fluoroquinolone use and this change. In addition, there was no association between increasing anti-pseudomonal cephalosporin use and cefepime resistant P. aeruginosa. No statistical relationship was seen with overall antibiotic use and the development of resistance in P. aeruginosa, suggesting that the development of resistance is associated with the use of individual agents, rather than overall antibiotic consumption. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 18 条
[1]  
AMSDEN GW, 1995, PRINCIPLES PRACTICE, P492
[2]   Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals [J].
Bhavnani, SM ;
Callen, WA ;
Forrest, A ;
Gilliland, KK ;
Collins, DA ;
Paladino, JA ;
Schentag, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (19) :1962-1970
[3]   The mutant selection window and antimicrobial resistance [J].
Drlica, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :11-17
[4]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[5]   Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin [J].
Gilbert, DN ;
Kohlhepp, SJ ;
Slama, KA ;
Grunkemeier, G ;
Lewis, G ;
Dworkin, RJ ;
Slaughter, SE ;
Leggett, JE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :883-892
[6]  
IANNINI P, 2001, PHARMACOTHERAPY S, V10, P111
[7]   Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa:: Our worst nightmare? [J].
Livermore, DM .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :634-640
[8]  
MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033
[9]  
MOHR J, 2001, P AM COLL CLIN PHARM
[10]  
NCCLS, 2003, NCCLS